D-焦谷氨酸叔丁酯 | 205524-46-5

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 谷氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: D-焦谷氨酸叔丁酯
• 中文别名: 5-氧代-d-脯氨酸1,1-二甲基乙酯；(R)-2-吡咯烷酮-5-甲酸叔丁酯
• 英文名称: tert-butyl (R)-5-oxopyrrolidine-2-carboxylate
• 英文别名: (R)-Tert-butyl 5-oxopyrrolidine-2-carboxylate；tert-butyl (2R)-5-oxopyrrolidine-2-carboxylate
• CAS: 205524-46-5
• 化学式: C₉H₁₅NO₃
• mdl: MFCD09261417
• 分子量: 185.223
• InChiKey: QXGSPAGZWRTTOT-ZCFIWIBFSA-N

物化性质

• 沸点：
  319℃
• 密度：
  1.099
• 闪点：
  147℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933790090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: D-Pyroglutamic acid tert-butyl ester
Synonyms: (R)-2-Pyrrolidone-5-carboxylic acid t-butyl ester

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: D-Pyroglutamic acid tert-butyl ester
CAS number: 205524-46-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H15NO3
Molecular weight: 185.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  D-焦谷氨酸叔丁酯 在 4-二甲氨基吡啶 、 正丁基锂 、 四丁基氟化铵 、 溶剂黄146 作用下， 以 四氢呋喃 、 正己烷 、 水 为溶剂， 反应 3.17h， 生成 (R)-tert-butyl-2-(tert-butoxycarbonylamino)-5-(6-hydroxybenzo[d]thiazol-2-yl)-5-oxopentanoate
  参考文献：
  名称：

  萤火虫萤光素类似物的合成及发光性能评估

  摘要：

  合成了五个新的萤火虫萤光素（1）类似物，并检查了它们的发光特性。在噻唑啉部分的修饰1被雇用含非环状氨基酸侧链产生类似物（2 - 4）和从氨基酸（派生杂环5和6连接到苯并噻唑部分）。虽然所有表现出化学发光活性的合成衍生物的甲酯，仅carboluciferin（6），具有吡咯啉基取代的苯并噻唑结构，具有生物发光（BL）活性（λ最大= 547nm）。AMP-碳荧光素（AMP =腺苷一磷酸）和AMP-萤火虫荧光素的生物发光研究结果表明，噻唑啉模拟部分的性质影响了产生有效BL所需的荧光素-荧光素酶反应的腺苷酸化步骤。此外，BL 6在活小鼠中从不同的1在其发光衰减速率较慢。

  DOI：

  10.1002/chem.201600278
• 作为产物：
  描述：

  醋酸叔丁酯 、 D-焦谷氨酸 在 高氯酸 作用下， 以 水 为溶剂， 以100%的产率得到D-焦谷氨酸叔丁酯
  参考文献：
  名称：

  萤火虫萤光素类似物的合成及发光性能评估

  摘要：

  合成了五个新的萤火虫萤光素（1）类似物，并检查了它们的发光特性。在噻唑啉部分的修饰1被雇用含非环状氨基酸侧链产生类似物（2 - 4）和从氨基酸（派生杂环5和6连接到苯并噻唑部分）。虽然所有表现出化学发光活性的合成衍生物的甲酯，仅carboluciferin（6），具有吡咯啉基取代的苯并噻唑结构，具有生物发光（BL）活性（λ最大= 547nm）。AMP-碳荧光素（AMP =腺苷一磷酸）和AMP-萤火虫荧光素的生物发光研究结果表明，噻唑啉模拟部分的性质影响了产生有效BL所需的荧光素-荧光素酶反应的腺苷酸化步骤。此外，BL 6在活小鼠中从不同的1在其发光衰减速率较慢。

  DOI：

  10.1002/chem.201600278

文献信息

• Synthesis of α‐Ketoamide‐Based Stereoselective Calpain‐1 Inhibitors as Neuroprotective Agents
  作者：Ammar Jastaniah、Irina N. Gaisina、Rachel C. Knopp、Gregory R. J. Thatcher

  DOI：10.1002/cmdc.202000385

  日期：2020.12.3

  potentially including ABT‐957 was optimized to yield diastereomerically pure compounds that are potent and selective for calpain‐1 over papain and cathepsins B and K. As the final oxidation step, with its optimized synthesis protocol, does not alter the configuration of the substrate, the synthesis of the diastereomeric pair (R)‐1‐benzyl‐N‐((S)‐4‐((4‐fluorobenzyl)amino)‐3,4‐dioxo‐1‐phenylbutan‐2‐yl)‐5‐oxopy

  钙蛋白酶抑制剂已被提议作为神经退行性疾病的候选药物，ABT-957 已进入阿尔茨海默病和轻度认知障碍的临床试验。ABT-957 的结构最近才被公开，由于 CNS 浓度不足以获得药效学效果，试验被终止。对可能包括 ABT-957 的 α-酮酰胺类肽模拟抑制剂系列的多步合成进行了优化，以产生非对映异构纯的化合物，这些化合物对 calpain-1 比木瓜蛋白酶和组织蛋白酶 B 和 K 更有效且具有选择性。作为最后的氧化步骤，其优化合成方案，不改变底物的构型，非对映体对 ( R )-1-苄基-N -(( S）-4 - （（4-氟苄基）氨基）-3,4-二氧代-1-苯基丁-2-基）-5-氧代吡咯烷-2-甲酰胺（图1c）和（- [R）-1-苄基- ñ - (( R )-4-((4-fluorobenzyl)amino)-3,4-dioxo-1-phenylbutan-2-yl)-5-oxopyrrolidine-2-carboxamide
• Copper-Catalyzed Coupling Reaction of (Hetero)Aryl Chlorides and Amides
  作者：Subhadip De、Junli Yin、Dawei Ma

  DOI：10.1021/acs.orglett.7b02326

  日期：2017.9.15

  amide is established to be an effective catalyst system for Goldberg amidation with inferior reactive (hetero)aryl chlorides, which have not been efficiently documented by Cu-catalysis to date. The reaction is well liberalized toward a variety of functionalized (hetero)aryl chlorides and a wide range of aromatic and aliphatic primary amides in good to excellent yields. Furthermore, the arylation of

  Cu 2 O / N，N'-双（噻吩-2-基甲基）草酰胺被确立为用较差的反应性（杂）芳基氯化物进行戈德堡酰胺化的有效催化剂体系，迄今为止，Cu催化还没有有效地证明这一点。 。反应很好地放宽了对各种官能化的（杂）芳基氯化物以及各种芳族和脂族伯酰胺的反应，收率非常好。此外，实现了内酰胺和恶唑烷酮的芳基化。本催化体系还完成了分子内的交叉偶联产物。
• Potent orally active inhibitors of angiotensin-converting enzyme (ACE).
  作者：KATSUHIRO IMAKI、SHIGERU SAKUYAMA、TAKANORI OKADA、MASAAKI TODA、MASAKI HAYASHI、TSUMORU MIYAMOTO、AKIYOSHI KAWASAKI、TADAO OKEGAWA

  DOI：10.1248/cpb.29.2210

  日期：——

  1-[3-Mercaptoalkanoyl] pyroglutamic acids and 1-[3-mercaptoalkanoyl]-4-hetero (oxa, thia and aza) pyroglutamic acids were prepared and their inhibitory activities against angiotensin-converting enzyme (ACE) were examined. (2S)-1-[(2S)-3-Mercapto-2-methylpropanoyl] pyroglutamic acid 2 was found to be the most potent orally active inhibitor of ACE of rabbit lung among the derivatives synthesized in the present study and appeared to have great potential for use as an oral antihypertensive agent.

  制备了 1-[3-巯基-2-甲基丙酰基]焦谷氨酸和 1-[3-巯基-2-甲基丙酰基]-4-杂（oxa、thia 和 aza）焦谷氨酸，并考察了它们对血管紧张素转换酶（ACE）的抑制活性。结果发现，在本研究合成的衍生物中，(2S)-1-[(2S)-3-巯基-2-甲基丙酰基]焦谷氨酸 2 是对兔肺血管紧张素转换酶（ACE）最有效的口服活性抑制剂，似乎极有潜力用作口服降压药。
• PYRIMIDINYL TYROSINE KINASE INHIBITORS
  申请人：BIOGEN IDEC MA INC.

  公开号：US20150158843A1

  公开（公告）日：2015-06-11

  The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

  本发明提供了化合物及其组合物，可用作布鲁顿酪氨酸激酶的抑制剂，并具有相应的理想特性。
• Inhibitors of Bruton's tyrosine kinase
  申请人：BIOGEN MA INC.

  公开号：US10189817B2

  公开（公告）日：2019-01-29

  The present invention provides a compound, solid forms, and compositions thereof, which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same. The present invention also provides methods of making provided compound and solid forms.

  本发明提供了一种化合物、固体形式及其组合物，它们可用作布鲁顿酪氨酸激酶的抑制剂，并表现出理想的特性。本发明还提供了制造所提供的化合物和固体形式的方法。

表征谱图